Cytophage Technologies Ltd.

TSXV:CYTO Stock Report

Market Cap: CA$17.5m

Cytophage Technologies Past Earnings Performance

Past criteria checks 0/6

Cytophage Technologies's earnings have been declining at an average annual rate of -88.9%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-88.9%

Earnings growth rate

-66.9%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth raten/a
Return on equity-149.1%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Cytophage Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:CYTO Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-850
31 Mar 240-850
31 Dec 230-540

Quality Earnings: CYTO is currently unprofitable.

Growing Profit Margin: CYTO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if CYTO's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare CYTO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CYTO has a negative Return on Equity (-149.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies